Hassan Foroughi-Asl
Overview
Explore the profile of Hassan Foroughi-Asl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
213
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wallander K, Haider Z, Jeggari A, Foroughi-Asl H, Gellerbring A, Lyander A, et al.
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831507
In this longitudinal study, cell-free tumour DNA (a liquid biopsy) from plasma was explored as a prognostic biomarker for gastro-oesophageal cancer. Both tumour-informed and tumour-agnostic approaches for plasma variant filtering...
2.
Bonfiglio S, Sutton L, Ljungstrom V, Capasso A, Pandzic T, Westrom S, et al.
Blood Adv
. 2023 Jan;
7(12):2794-2806.
PMID: 36696464
Patients with chronic lymphocytic leukemia (CLL) progressing on ibrutinib constitute an unmet need. Though Bruton tyrosine kinase (BTK) and PLCG2 mutations are associated with ibrutinib resistance, their frequency and relevance...
3.
Mansouri L, Thorvaldsdottir B, Sutton L, Karakatsoulis G, Meggendorfer M, Parker H, et al.
Leukemia
. 2023 Jan;
37(2):504.
PMID: 36635392
No abstract available.
4.
Mansouri L, Thorvaldsdottir B, Sutton L, Karakatsoulis G, Meggendorfer M, Parker H, et al.
Leukemia
. 2022 Dec;
37(2):339-347.
PMID: 36566271
Recent evidence suggests that the prognostic impact of gene mutations in patients with chronic lymphocytic leukemia (CLL) may differ depending on the immunoglobulin heavy variable (IGHV) gene somatic hypermutation (SHM)...
5.
Franzen O, Ermel R, Cohain A, Akers N, Di Narzo A, Talukdar H, et al.
Science
. 2016 Aug;
353(6301):827-30.
PMID: 27540175
Genome-wide association studies (GWAS) have identified hundreds of cardiometabolic disease (CMD) risk loci. However, they contribute little to genetic variance, and most downstream gene-regulatory mechanisms are unknown. We genotyped and...